ATXA Therapeutics is a clinical-stage pharmaceutical company dedicated to advancing innovative and life-changing treatments for cardiopulmonary diseases. With a team of leading experts in the field, including scientists, clinicians, and commercial strategists, ATXA is committed to developing novel antagonists of the Thromboxane Receptor (TP), a key driver of disease in the heart and lungs. Founded by Professor Therese Kinsella in 2015, ATXA brings together over 20 years of research and prestigious funding to elucidate the biology and signaling of the human prostanoid receptors in disease settings.

Headquartered in Dublin, Ireland, ATXA aims to develop therapies for cardiopulmonary indications that significantly improve on existing standard-of-care and address unmet medical needs. With a pipeline of highly selective small molecule drugs, ATXA's current focus is on developing NTP42, a lead compound for the treatment of Pulmonary Arterial Hypertension (PAH), offering new hope and improved treatment options for patients. ATXA's research and development efforts are supported by a growing global patent estate and significant grants from organizations like Enterprise Ireland and the European Union's Horizon 2020 SME Instrument funding scheme.

For cutting-edge treatments in cardiopulmonary diseases, trust ATXA Therapeutics